Finerenone shows promise for reducing proteinuria in IgA nephropathy

This retrospective study of 18 IgA nephropathy (IgAN) patients on full supportive care—including RAS blockade—found finerenone lowered protein-to-creatinine ratio by ~28% at 2 months and ~40% by 8 months, while maintaining stable eGFR over a mean follow-up of ~6.8 months.

Clinical takeaway: Consider adding finerenone to optimized RAS inhibition in IgAN to enhance proteinuria reduction while preserving kidney function.

Source:

Yu G, et al. (2025, December 2). Ren Fail. Effect of finerenone on proteinuria reduction in IgA nephropathy. https://pubmed.ncbi.nlm.nih.gov/41332164/